Navigation Links
Facial Injectables Emerge From the Recession
Date:11/30/2009

WALTHAM, Mass., Nov. 30 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the nearly $1.2 billion global facial injectable market declined by almost 5% over 2008 as patients chose to delay or forego treatment as a result of the economic crisis. The market will, however, begin recovery in 2010, and by 2014, will return to the strong pre-recession growth rates of over 15%. MRG's facial injectable series, which includes separate reports on North America, Europe, Asia Pacific, and Latin America, finds that many manufacturers are refining marketing strategies and strengthening product portfolios in order to establish optimal market position in the coming years.

To combat financial pressures and bolster share in advance of economic recovery, some firms that had longstanding plans to enter the US market were granted FDA approval and launched new products in 2009 in hopes of stimulating interest and adoption amongst new practitioners and patients. In the US, notable releases included the highly anticipated Dysport by Ipsen and Medicis Pharmaceutical, and the approval of Sculptra Aesthetic by sanofi-aventis. In the European facial injectable market, Ipsen and Galderma launched Azzalure, a version of Dysport that is rebranded for aesthetic use in Europe. Although these competitors launched their products during difficult financial times, the interest stimulated through these launches will carry through into recovery, positioning the firms favorably for improved cosmetic procedure volumes.

"The launch of these new products has generated a lot of media attention, owing in part to the extensive marketing campaigns and promotional activities that manufacturers are engaging in," says Lisa Shantz, Analyst at MRG. "Although these newly-introduced products will have a greater impact when the market begins to recover in 2010, many physicians and patients are now much more aware of the different types and brands of products at their disposal. As new manufacturers continue to enter the market, competitive pricing pressures will make treatments increasingly affordable for patients, spurring procedure volume growth."

MRG's global facial injectable series examines how the botulinum toxin, hyaluronic acid dermal filler, particle and polymer filler, and collagen filler markets were affected by the recession and just how quickly they will return to healthier growth rates. Each report includes detailed, segmented analyses of procedures by product type, unit sales, average selling prices, market revenues, and competitor shares. The North American facial injectable report also segments injections by the area of the face in which the products are injected.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 ext. 101
akrohn@mrg.net

Elizabeth Marshall
Decision Resources Inc.
781-296-2563
emarshall@dresources.com

SOURCE Millennium Research Group


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Promising Results in Treating Facial Bruising From Injectables
2. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
3. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
4. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
5. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
6. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
7. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Brain Cancer patients in the Mid-South ... West Cancer Center . Optune™, a portable ... cell replication causing death of cancer cells, is the ... show a significant extension in overall survival rates for ... Cancer Center is the only medical center in ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... seeking candidates for the Board of Commissioners. Individuals interested in volunteer board service ... with diversity of clinical practice settings and across allied health to contribute to ...
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... Rock, AR (PRWEB) , ... February 11, 2016 , ... ... in their community by announcing a new fundraiser in support of a local boy ... also hopes the campaign will bring awareness to, and rally support for, all local ...
(Date:2/11/2016)... ... 11, 2016 , ... Be Well Medical Group (Be Well) is ... Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group ... in the convenience of their homes, offices or at the practices’ local office. It ...
Breaking Medicine News(10 mins):